Sun Pharmaceutical Industries Limited has informed the Exchange about Investor Presentation
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma filed its July 2025 Investor Presentation detailing FY25 (ended March 2025) results: total sales of Rs 520,412 mn (up 9% YoY), EBITDA of Rs 152,717 mn at a 29% margin (up 17.3%), and adjusted net profit of Rs 119,844 mn (up 19%). India formulations led at 33% of revenue (Rs 169,230 mn) with 8.3% domestic market share, followed by US formulations at 31% (Rs 162,403 mn) where it is the 12th largest generics player. Specialty/Innovative Therapies contributed 20% of sales, led by Ilumya which posted $681 mn in FY25. The company has a net cash position (cash Rs 113 Bn vs gross debt Rs 18.7 Bn), a market cap of US$ 46 Bn, and flagged the recent acquisition of Checkpoint Therapeutics. Management guided to mid-to-high single digit consolidated topline growth for FY26 with focus on improving return ratios.
Reinforces Sun Pharma's position as a financially strong, debt-free pharma major with rising margins (EBITDA margin up from 25.3% in FY21 to 29% in FY25) and a healthy US specialty pipeline. Conservative FY26 growth guidance and absence of major negative surprises should support steady investor sentiment.